NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men ID4059

Provisional Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • Radius Health (abaloparatide) Patient/carer groups • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Back Care • Pain Concern • Pain UK • Royal Osteoporosis Society • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis Healthcare professional groups • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Institute of Radiology • British Myology Society • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association • Primary Care Rheumatology and Musculoskeletal Medicine Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • Accord Healthcare (alendronic acid, ibandronic acid, risedronate sodium) • Accord-UK (ibandronic acid, raloxifene) • Amdipharm Mercury Company (risedronate sodium) • Amgen (denosumab) • Aristo Pharma (risedronate sodium, strontium ranelate) • Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium) • Atnahs Pharma UK (ibandronic acid) • Aurobindo Pharma - Milpharm (risedronate sodium) • Dr. Reddy's Laboratories (UK)

Consultees	**Commentators (no right to submit or appeal)**
• Society and the College of Radiographers • Society of Endocrinology • UK Clinical Pharmacy Association <u>Others</u> • Department of Health and Social Care • NHS England • NHS Leeds CCG • NHS Telford & Wrekin CCG • Welsh Government	(zoledronic acid) • Eli Lilly and Company (teriparatide) • Gedeon Richter (UK) (teriparatide) • Mylan (ibandronic acid) • Novartis Pharmaceuticals (zoledronic acid) • Ranbaxy (UK) a Sun Pharmaceutical Company (zoledronic acid) • Sandoz (ibandronic acid, risedronate sodium) • Seacross Pharmaceuticals (zoledronic acid) • Teva UK (teriparatide) • Thornton & Ross (teriparatide) • UCB Pharma (romosozumab) • Vygoris (raloxifene) • Zentiva (ibandronic acid) <u>Relevant research groups</u> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • Institute for Ageing and Health • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

